BAYRY - Bayer Aktiengesellschaft

Other OTC - Other OTC Delayed Price. Currency in USD
18.39
+0.44 (+2.45%)
As of 10:13AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close17.95
Open18.47
Bid0.00 x 0
Ask0.00 x 0
Day's Range18.39 - 18.51
52 Week Range14.61 - 24.31
Volume81,611
Avg. Volume570,266
Market Cap68.565B
Beta (3Y Monthly)1.13
PE Ratio (TTM)9.97
EPS (TTM)1.84
Earnings DateN/A
Forward Dividend & Yield0.78 (4.46%)
Ex-Dividend Date2019-04-29
1y Target Est26.11
Trade prices are not sourced from all markets
  • Barrons.com

    Elanco Animal Health Stock Gets an Upgrade, Despite Bayer Deal Worries

    After a week of will they/won’t they drama around a rumored merger between Elanco Animal Health and Bayer A.G., one analyst at UBS is upgrading Elanco stock.

  • Regeneron Gets FDA Nod for Eylea Injection Prefilled Syringe
    Zacks

    Regeneron Gets FDA Nod for Eylea Injection Prefilled Syringe

    Regeneron (REGN) receives FDA approval for a prefilled syringe of its ophthalmology drug, Eylea.

  • Deciphera's GIST Drug Succeeds in Pivotal Study, Stock Up 80%
    Zacks

    Deciphera's GIST Drug Succeeds in Pivotal Study, Stock Up 80%

    Deciphera's (DCPH) pipeline candidate, ripretinib, improves progression free survival in a pivotal study evaluating it in previously treated, advanced gastrointestinal stromal tumors.

  • Reuters

    AmVac sees Brazil as prime user of new pesticide application system

    Executives at agrochemicals company American Vanguard Corp, or AmVac, believe farmers in Brazil will become the prime users of a new pesticide application system being tested in the United States. The SIMPAS system allows farmers to apply multiple crop protection or fertilizer products at one given time while calibrating the exact amount of inputs to use in specific parts of the field, potentially minimizing dosage and optimizing resources, the executives said on Monday. AmVac plans to introduce the system in Brazil one year after the full U.S. launch scheduled for 2021, Chief Operating Officer Bob Trogele said ahead of a trade show in São Paulo.

  • Elanco Narrows Guidance Amid Spread of African Swine Fever
    Bloomberg

    Elanco Narrows Guidance Amid Spread of African Swine Fever

    (Bloomberg) -- Elanco Animal Health Inc. narrowed its sales forecast for the year as a worsening outbreak of a deadly swine flu ravages the pork industry in Asia.The company, which was spun off last year from drugmaker Eli Lilly & Co., reined in the higher end of its revenue outlook, saying it now sees 2019 sales of $3.08 billion to $3.12 billion, compared with the $3.08 billion to $3.14 billion it had forecast in May.African swine fever has led to the slaughter of millions of animals in China as officials seek to contain the outbreak and limit the damage to the country’s pork producers. The virulent flu jumped from Africa to Europe and spread quickly in Asia. For companies like Elanco, the culling of livestock has led to lower demand for medicines and other products.“I haven’t seen something like this in my 30 years working in animal health,” said Elanco Chief Executive Officer Jeff Simmons in a telephone interview. He said that swine fever is the most significant headwind the company faces. The disease is expected to cut into Elanco’s sales by $40 million to $50 million this year, the company said.Elanco is meanwhile weighing steps to get bigger. Last week, Bloomberg reported that Elanco is attempting to reach a deal to combine with Bayer AG’s animal-health unit.Chief Financial Officer Todd Young said on a conference call that Elanco is postponing the initiation of a dividend so the company can use its cash “in the most productive way possible.”Shares of Elanco gained as much as 2.9% to $30.40 in New York on Tuesday.Street SkepticismWall Street has been skeptical about Elanco’s bid for the Bayer division. Since July 8, the day before Reuters reported that the companies were in talks, Elanco’s shares are down about 9%.While Bayer prefers a deal with Elanco, no final agreements have been reached and the talks could drag on or fall apart, people familiar with the matter told Bloomberg. Bayer may proceed with its previous plans for a broader auction process if it can’t agree on terms with Elanco by early September, one of the people said at the time.Asked repeatedly about the possible combination with Bayer on the call with investors, Simmons said Elanco is always “evaluating vectors of risk and opportunity.” He declined to comment further on the potential deal.“We believe we have the scale and the global reach that we need,” Simmons said in the telephone interview. “We’ll continue to expand and accelerate this strategy, we’ll continue to bolt-on.”Elanco’s pet businesses helped offset the sales declines in the farm unit in the most recent quarter, with disease prevention sales increasing 4% from a year earlier to $223.4 million and therapeutics sales rising 22% to $83.4 million.Second-quarter adjusted earnings were 28 cents a share, the company said in a statement, topping an average of analysts’ estimates.(Updates with comments from conference call in sixth paragraph)To contact the reporter on this story: Riley Griffin in New York at rgriffin42@bloomberg.netTo contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Barrons.com

    Elanco Stock Jumps Because There’s No Sign of Bayer Merger Yet

    The company didn’t announce a reported merger with Bayer A.G. that had been expected to be announced Tuesday.

  • Reuters

    No-deal Brexit could deepen Europe's shortage of medicines - experts

    As the Oct. 31 deadline for Britain to leave the European Union approaches, health professionals are warning that shortages of some medicines could worsen in Europe in the event of a no-deal Brexit. Britain's food and drink lobby warned last week that the country would experience shortages of some fresh foods if there is a disorderly no-deal Brexit.

  • AVEO Pharmaceuticals (AVEO) Q2 Earnings Beat, Revenues Lag
    Zacks

    AVEO Pharmaceuticals (AVEO) Q2 Earnings Beat, Revenues Lag

    AVEO Pharmaceuticals' (AVEO) loss is narrower than expected in the second quarter of 2019. However, revenues fall short of estimates.

  • Barrons.com

    Bayer Stock Will Soar 30% If It Strikes $8 Billion Roundup Settlement, But It’s a Big If

    German chemical company Bayer’s stock could soar if the company can agree to settle more than 18,000 lawsuits claiming that its Roundup weedkiller causes cancer.

  • For Bayer, a Roundup Deal Would Be Billions Well Spent
    Bloomberg

    For Bayer, a Roundup Deal Would Be Billions Well Spent

    (Bloomberg Opinion) -- Bayer AG shareholders are daring to imagine a future free of the litigation that has dogged the pharma group’s Roundup weedkiller. It’s an increasingly plausible scenario, and one investors are itching to price in.Evidence is mounting that the German drugmaker is serious about settling the thousands of claims alleging Roundup is responsible for cancer. Bayer’s lawyers have suggested a deal worth between $6 billion and $8 billion, Bloomberg News reported on Friday. The talks are sufficiently advanced that lawyers are seeking a delay to upcoming court cases.Bayer had been energetically contesting the claims, insisting that Roundup is safe when used as directed. The stock jumped as much as 11%, adding 6.6 billion euros ($7.4 billion) to the company’s market value, highlighting the commercial case for being pragmatic and settling rather than fighting on.The size of the possible settlement looks close to what analysts had predicted using the drug industry as a precedent. Bloomberg Intelligence put the likely cost of a deal at $6 billion to $10 billion. As things stand, it’s not clear if Bayer’s range is an opening shot. Lawyers for the plaintiffs are seeking more than $10 billion. Whether a deal can be reached, and its final cost, remain to be seen. Chief Executive Officer Werner Baumann has chosen his words carefully, saying last month the company would be open to a settlement that was reasonably priced and that definitively ceased litigation.His challenge is to balance the hard costs of a deal with the boost to the share price it could create. Bayer can afford to pay – but it would be a stretch. Its $39 billion of net debt puts leverage at 3.3 times the last 12 months’ Ebitda. A $10 billion settlement would push leverage to roughly four times Ebitda. That’s still less than what it was immediately after the company’s takeover of Monsanto Co. last year, the fateful deal that brought Roundup with it.The upside for shareholders looks to be more substantial. Even after Friday’s jump, Bayer trades on 8.5 times this year’s estimated Ebitda, less than the 12 times average of its peers in the pharmaceutical industry. Suppose worries about Roundup fade, allow for a conglomerate discount to reflect the company’s unproven model of combining crop and life sciences, and say the stock re-rates to 10 times. Bayer’s enterprise value would then be 119 billion euros. Deduct net debt and, say, $10 billion for a settlement and the equity would be worth 71 billion euros, 17% more than the company’s current market value.Baumann has seen the market’s appetite for clarity here. His investors want him to get this done and to get on with the next big job – making the Monsanto deal deliver.To contact the author of this story: Chris Hughes at chughes89@bloomberg.netTo contact the editor responsible for this story: Edward Evans at eevans3@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Chris Hughes is a Bloomberg Opinion columnist covering deals. He previously worked for Reuters Breakingviews, as well as the Financial Times and the Independent newspaper.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.

  • Financial Times

    Bayer boosted by report of $8bn settlement proposal in pesticide legal battle

    Shares in Bayer jumped 8 per cent on Friday after a media report suggested that the German chemicals and pharmaceuticals group was in talks to settle its sprawling legal battle in the US over the Roundup pesticide for as much as $8bn. Bayer has been under intense pressure from shareholders to put an end to the avalanche of legal claims alleging that Roundup, a weed killer that contains glyphosate, causes cancer. According to a report by Bloomberg, Bayer’s legal team is currently holding talks in New York City with plaintiff lawyers aimed at settling all outstanding and future claims.

  • Bayer mediator dismisses report of $8 bln Roundup settlement
    Reuters

    Bayer mediator dismisses report of $8 bln Roundup settlement

    NEW YORK/FRANKFURT (Reuters) - Bayer AG has not offered to pay billions of dollars to settle claims in the United States related to the Roundup herbicide, mediator Ken Feinberg said, dismissing a report to that effect which drove its shares as much as 11% higher. "Bayer has not proposed paying $8 billion to settle all the U.S. Roundup cancer claims. Such a statement is pure fiction," Feinberg said in an email on Friday.

  • Bayer mediator dismisses report of $8 billion Roundup settlement
    Reuters

    Bayer mediator dismisses report of $8 billion Roundup settlement

    NEW YORK/FRANKFURT (Reuters) - Bayer AG has not offered to pay billions of dollars to settle claims in the United States related to the Roundup herbicide, mediator Ken Feinberg said, dismissing a report to that effect which drove its shares as much as 11% higher. "Bayer has not proposed paying $8 billion to settle all the U.S. Roundup cancer claims. Such a statement is pure fiction," Feinberg said in an email on Friday.

  • TheStreet.com

    Bayer Shares Surge on Report of $8 Billion Roundup Weedkiller Settlement

    Bayer shares traded sharply higher Friday, well outpacing the broader German market, following a report that suggested it could pay $8 billion to settle thousands of lawsuits linked to its Roundup weedkiller.

  • Benzinga

    Bayer To Buy Out Stem Cell Therapy Company BlueRock For Up To $600M

    German chemicals and pharma company Bayer AG (OTC: BAYRY) announced an agreement Thursday to buy out the remaining stake it does not already own in Cambridge, Massachusetts-based BlueRock Therapeutics, a privately held stem cell therapy company. BlueRock was established in 2016 as a joint venture between Bayer and Versant Ventures, with the former holding a 40.8% stake. BlueRock's cell therapy portfolio focuses on neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell, or iPSC platform.

  • Bayer buys BlueRock in $600 million bet on stem cell therapies
    Reuters

    Bayer buys BlueRock in $600 million bet on stem cell therapies

    German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics, stepping up investment in a promising new medical area to revive its drug development pipeline. Having established BlueRock as part of a 2016 joint venture with Versant Ventures, Bayer will acquire the remaining 59.2% stake for about $240 million upfront and an additional $360 million depending on certain development achievements, it said on Thursday. BlueRock, valued at about $1 billion by the deal, is working on induced pluripotent stem cells (iPSC), made by reprogramming mature body cells to behave like embryonic stem cells that are injected to restore diseased tissue in patients.

  • MarketWatch

    Bayer to acquire biotech BlueRock Therapeutics

    Bayer AG is acquiring BlueRock Therapeutics, a privately-held U.S.-based biotech developing engineered cell therapies in the areas of neurology, cardiology and immunology, the companies announced Thursday. BlueRock was established in 2016 through a joint venture between Bayer and Versant Ventures. Germany-based Bayer currently holds a 40.8% stake and will acquire the rest for around $240 million. Bayer could also pay an additional $360 million if BlueRock meets certain research milestones, valuing BlueRock at around $1 billion. The transaction is expected to close during the third quarter of 2019. "This acquisition marks a major milestone on our path towards a leading position in cell therapy," said Stefan Oelrich, president of Bayer's pharmaceuticals division. Shares of Bayer have fallen 3.1% in the year to date through Wednesday, while the S&P 500 has gained 15%.

  • Financial Times

    Bayer to buy rest of US biotech company in rare offensive move

    Bayer has agreed to take full control of BlueRock Therapeutics, in a deal that values the US biotech company at up to $1bn. The German pharmaceuticals and chemicals group will pay $240m upfront, and will pay an additional $360m upon achievement of “predefined development milestones”. Bayer already owns 41 per cent of BlueRock, which it set up as a joint venture with Versant Ventures in 2016.

  • Elanco, Bayer Are Aiming to Reach Animal-Health Deal Next Week
    Bloomberg

    Elanco, Bayer Are Aiming to Reach Animal-Health Deal Next Week

    (Bloomberg) -- Elanco Animal Health Inc., the business Eli Lilly & Co. listed last year, is aiming to reach an agreement as soon as next week to combine with Bayer AG’s animal-health unit, people with knowledge of the matter said.The companies hope to announce a deal around the time of Elanco’s Aug. 13 earnings release, the people said, asking not to be identified as the discussions are private. Elanco, which has a market value of about $12.3 billion, plans to pay at least part of the acquisition cost using stock, the people said.Elanco lost 4.2% Wednesday to close at $31.47. Bayer rose as much as 2.6% early Thursday in Frankfurt.Bayer is selling units to sharpen its focus after the $63 billion purchase of Monsanto, which saddled it with thousands of lawsuits claiming that the Roundup weedkiller it acquired in that deal causes cancer. The German giant agreed to unload its majority stake in a chemicals venture Wednesday in a deal valued at $3.9 billion, and two Roundup trials have been delayed as pressure builds on Chief Executive Officer Werner Baumann to fashion a settlement.Bayer would get a significant minority stake in Elanco under the deal being discussed, according to another person. The companies are currently hammering out potential antitrust issues by identifying which businesses they will likely need to sell to gain regulatory approval, the person said.While Bayer prefers a deal with Elanco, no final agreements have been reached and the talks could drag on or fall apart, the people said. Bayer may proceed with its previous plans for a broader auction process if it can’t agree on terms with Elanco by early September, one person said.Serial AcquirerA deal between Elanco and Bayer would preempt a sale process that was expected to be one of Europe’s most hotly contested deal situations this year. It had attracted a flurry of initial interest from buyout firms ranging from KKR & Co. to Blackstone Group Inc. and CVC Capital Partners, which have increasingly been bidding against each other as they try to spend the record amounts of capital the industry has amassed.Bayer said in a statement that it’s on track with plans to exit the animal-health business and its primary focus is on a sale. The German company also continues to consider all value-maximizing options, it said in the statement, declining to comment further.Elanco has grown rapidly through at least 10 acquisitions since 2007, including the $5.4 billion takeover of Novartis AG’s animal-health unit. A representative for Elanco, which is based outside Indianapolis, declined to comment.Ambitious BetsThe sale of Bayer’s animal-health unit was expected to fetch as much as 8 billion euros ($9 billion), Bloomberg News has reported. The process was initially slated to kick off in the second quarter, people with knowledge of the matter said in March, though Bayer has repeatedly pushed back the start of the auction.The Bayer business offers medicine and antibiotics to farm animals and pets. The division’s best-selling product line is the Advantage flea, tick and worm treatments for small animals.Drugmakers including Lilly, Bayer and Pfizer Inc. have all offloaded their animal-health units in recent years. The businesses are often stable, profitable operations that go unrecognized inside larger pharmaceutical firms increasingly focused on ambitious research bets.(Updates with shares in third paragraph.)\--With assistance from Tim Loh and Nabila Ahmed.To contact the reporters on this story: Riley Griffin in New York at rgriffin42@bloomberg.net;Dinesh Nair in London at dnair5@bloomberg.net;Manuel Baigorri in Hong Kong at mbaigorri@bloomberg.netTo contact the editors responsible for this story: Liana Baker at lbaker75@bloomberg.net, ;Drew Armstrong at darmstrong17@bloomberg.net, ;Fion Li at fli59@bloomberg.net, Ben Scent, Amy ThomsonFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Financial Times

    Bayer’s Monsanto acquisition leaves it with a toxic legacy

    FT premium subscribers can click here to receive Due Diligence every day by email. In that spirit, we’ve launched a Fantasy Premier League for our readers to compete against DD writers and FT reporters.

  • Reuters

    UPDATE 1-Bayer, Elanco aiming to reach animal-health deal next week - Bloomberg

    Germany's Bayer AG and U.S. drug firm Elanco Animal Health Inc aim to reach an agreement to combine their pet-health businesses as soon as next week, Bloomberg reported https://www.bloomberg.com/news/articles/2019-08-07/elanco-bayer-said-aiming-to-reach-animal-health-deal-next-week on Wednesday, citing people with knowledge of the matter. Elanco plans to pay for at least a part of the deal with its stock and any deal would likely be announced around Elanco's earnings release next week, the report said. Reuters reported last month that Bayer had approached Elanco to discuss the possible combination that would create an industry giant.